Human immunodeficiency virus initiation

As might be predicted from these similarities between PNS and CNS, many disease entities can affect both these tissues. It should be noted, however, that the clinical expression of such diseases is variable and is sometimes restricted to the PNS. For example, patients with thiamine deficiency may display symmetrical distal sensorimotor polyneuropathy without accompanying CNS degeneration. Untreated infection with human immunodeficiency virus (HIV) may cause early polyneuropathy, with dementia appearing months or years later. Similarly, patients with sulfatidase deficiency or adrenoleukodystrophy may present initially with polyneuropathy, while their CNS dysfunction remains clinically undetectable. 

Replication of the human immunodeficiency virus (mV), the causative agent of AIDS, is susceptible to targeted interventions, because several virus-specific metabolic steps occur in infected cells (A). Viral RNA must first be transcribed into DNA, a step catalyzed by viral reverse transcriptase." Double-stranded DNA is incorporated into the host genome with the help of viral inte-grase. Under control by viral DNA, viral replication can then be initiated, with synthesis of viral RNA and proteins (including enzymes such as reverse transcriptase and integrase, and structural proteins such as the matrix protein lining the inside of the viral envelope). 

Tenofovir is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of tenofovir have not been established in patients coinfected with HBV and human immunodeficiency virus (HIV). Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV and have discontinued tenofovir. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who discontinue tenofovir and are coinfected with HBV and HIV. If appropriate, initiation of anti-hepatitis B therapy may be warranted. 

Acquired immune deficiency syndrome (AIDS) was initially described in the USA in 1981, although sporadic cases probably occurred for at least two decades prior to this. By 1983, the causative agent, now termed human immunodeficiency virus (HIV), was identified. HIV is a... 

Pyrrolopyridines substituted at the 2-position of dipyridodiazepinones have been prepared for study as nonnucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase <1997JME2430>. Compound 141, synthesized from pyrrolo[2,3-, ]pyridine as a starting material, has emerged as a novel inhibitor of HIV-1. Compound 141 acts by interfering with the initial viral entry process <2003JME4236>. 

Guadalupe M, Sankaran S, George MD et al (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 16 8236-8247... 

Reports that colchicine showed promising activity as an inhibitor of human immunodeficiency virus (HIV) replication (133,134) initiated the synthesis of derivatives of colchicine and thiocolchicine as potential inhibitors of HIV replication in H9 lymphocytic cells (135). Colchicine was found to be slightly active at nontoxic doses. All the other compounds, which were found inactive in this assay, were derivatives of colchiceine and/or A/-deacetylcolchicine. It is well established that both of these structural changes reduce dramatically binding to tubulin, and the reported results are, therefore, not completely surprising. 

Enfuvirtide (Fuzeon , T-20, Ro 29-9800, Hoffmann-La Roche) is a 36-amino acid synthetic peptide with a molecular weight of 4492 Da. It selectively inhibits human immunodeficiency virus (HIV) fusion to the host cell membranes [73]. The N-terminus of the molecule is acetylated and the C-terminus is amidated. A metabolite, M-20, is deamidated at the C-terminus. An ELISA method was initially used during drug development of this compound, but the decision was made to develop and validate an LC-ESI-MS/MS method for the simultaneous determination of enfuvirtide and M-20 for PK studies to support the NDA submission of this product [53]. Some of the issues of LC-ESI-MS/MS application for peptide bioanalysis are highlighted in the following. 

The value of spotting the unusual has been demonstrated by a number of infectious disease outbreaks in the United States. A classic example is the initial reports of the human immunodeficiency virus epidemic. Alert clinicians in California and New York City noted clusters of rare illnesses, Kaposi s sarcoma and Pneumocystis carinii pneumonia, among homosexual male clients in their practices (CDC, 1981a, 1981b). In May 1993, a New Mexico medical examiner reported two deaths from acute respiratory failure 5 days apart (CDC, 1993). 

Elegant studies have been carried out to investigate the structural and biochemical aspects of virus-cell fusion. Although influenza virus hemagglutinin and human immunodeficiency virus (HIV) gpl20 have been the best-studied models, numerous examples of this class I type fusion mechanism have been described. These experiments have shown that fusion is initiated by the formation of a trimeric coiled-coil helix adjacent to the fusion peptide on the virus exterior, the insertion of this fusion peptide into the host cell membrane, and the subsequent formation of a six-helix bundle (Skehel and Wiley, 1998). 

Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, PoUs M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 2003 41 4531-4536. 

Honda M, Yasuoka A, Aoki M, Oka S. A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Intern Med 1999 38(3) 302-3. 

The third use of an investigation is for prognosis, which may be considered as the assessment of risk, and complements the diagnostic application. For example, the measurement of human immunodeficiency virus (HIV) viral load foEowing initial diagnosis of HIV infection predicts the time interval before immune cohapse if the condition is not treated. 

An interesting example of polymorphic structure differentiation is that of human immunodeficiency virus (HIV) protease inhibitors. The HIV protease inhibitors pose a serious problem in their bioavailability. Invirase showed only modest market performance, and it was soon superseded by drugs, such as ritonavir (Norvir) and indinavir sulfate (Crixivan ) that had better bioavailability. Three years after initial approval, saquinavir was reintroduced in a formulation with sixfold higher oral bioavailability relative to the original product. Ritonavir was originally launched as a semisolid dosage form, in which the waxy matrix contained the dispersed drug in order to achieve acceptable oral bioavailabiUty. Two years after its introduction, ritonavir... 

---